Imunon, Inc.
corporate_fare Company Profile
Imunon, Inc. (NASDAQ:IMNN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for IMNN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for IMNN spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- NCI Partners with IMUNON to Expand IMNN-001 into New Cancer Indications
- Imunon Q2 2026: $6.9M Cash, Going Concern Warning, and $10M Financing Closed
- Imunon Q2 2026: $6.9M Cash, Phase 3 Enrollment on Track, R&D Day Set
- Imunon Posts $2.8M Q2 Loss, $6.9M Cash; Ovarian Cancer Trial Enrollment Ahead of Plan
- Imunon's Ovarian Cancer Trial Enrollment Exceeds Forecast, Completion Set for Q2 2029
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for IMNN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-16.
ATM Program Expanded · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →